FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative Regulatory Analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Cancers, Erscheinungsjahr: 2020, Jahrgang: 12, Heft: 2, E-ISSN: 2072-6694,Artikelnummer: 437
- Ereignis
-
Veröffentlichung
- (wo)
-
Leipzig
- (wer)
-
Universitätsbibliothek Leipzig
- (wann)
-
2023
- Urheber
-
Leo, Chandra P.
Hentschel, Bettina
Szucs, Thomas D.
Leo, Cornelia
- URN
-
urn:nbn:de:bsz:15-qucosa2-846909
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 08:49 UTC
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Leo, Chandra P.
- Hentschel, Bettina
- Szucs, Thomas D.
- Leo, Cornelia
- Universitätsbibliothek Leipzig
Entstanden
- 2023
Ähnliche Objekte (12)
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs
Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA
FDA drug approvals: Time Is money!
EMA-FDA Parallel Scientific Advice: Optimizing Development of Medicines in the Global Age
Mining FDA drug labels for medical conditions
The First FDA-Approved Antibody-Drug Conjugate
The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis
Considering Global Development? Insights from Applications for FDA Breakthrough Therapy and EMA PRIME Designations
FDA
FDA
FDA
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs
Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA
FDA drug approvals: Time Is money!
EMA-FDA Parallel Scientific Advice: Optimizing Development of Medicines in the Global Age
Mining FDA drug labels for medical conditions
The First FDA-Approved Antibody-Drug Conjugate
The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis
Considering Global Development? Insights from Applications for FDA Breakthrough Therapy and EMA PRIME Designations
FDA
FDA
FDA
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs
Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA
FDA drug approvals: Time Is money!
EMA-FDA Parallel Scientific Advice: Optimizing Development of Medicines in the Global Age
Mining FDA drug labels for medical conditions
The First FDA-Approved Antibody-Drug Conjugate
The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis
Considering Global Development? Insights from Applications for FDA Breakthrough Therapy and EMA PRIME Designations
FDA
FDA